Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

H-076

Supelco

9-Hydroxyrisperidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H27FN4O3
CAS Number:
144598-75-4
Molecular Weight:
426.48
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

shipped in

wet ice

storage temp.

−20°C

SMILES string

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCC(O)C5=N1

InChI

1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3

InChI key

PMXMIIMHBWHSKN-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356)

Related Categories

General description

A Snap-N-Spike® Reference Solution suitable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Risperidone European Pharmacopoeia (EP) Reference Standard

R1000600

Risperidone

N-Desmethylclozapine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-048

N-Desmethylclozapine solution

Clozapine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-059

Clozapine solution

Risperidone United States Pharmacopeia (USP) Reference Standard

USP

1604654

Risperidone

Islam Rasem Younis et al.
Journal of clinical psychopharmacology, 33(2), 152-156 (2013-02-21)
The Food and Drug Administration recently approved Invega for the treatment of schizophrenia in adolescents 12 to 17 years. If dosing recommendations for this population would have been based only on the results of the single efficacy trial included in
Paliperidone-related Pisa syndrome.
Po-Ren Teng et al.
Journal of clinical psychopharmacology, 33(1), 129-131 (2013-01-05)
Daniel Martín Fernández-Mayoralas et al.
Clinical neuropharmacology, 35(5), 227-230 (2012-09-01)
Paliperidone is the main active metabolite of risperidone, with certain pharmacokinetic and tolerability characteristics that suggest it may be used in special groups, such as children. Our purpose is to document the clinical experience with the use of paliperidone in
Treating residual insomnia in schizophrenia: examining the options.
C Andrade et al.
Acta psychiatrica Scandinavica, 127(1), 11-11 (2012-12-18)
M Treur et al.
Journal of medical economics, 15 Suppl 1, 26-34 (2012-09-29)
Paliperidone Extended Release OROS (ER) is a new atypical antipsychotic for the treatment of schizophrenia. The objective is, based on a previously published model, to analyze the clinical and economic effects of Paliperidone ER in a Spanish setting compared to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service